Rosiglitazone prevents the impairment of human islet function induced by fatty acids: Evidence for a role of PPARγ2 in the modulation of insulin secretion

American Journal of Physiology - Endocrinology and Metabolism

Volumn 286, Issue 4 49-4, 2004, Pages

  Lupi, R ^a   Del Guerra, S ^a   Marselli, L ^a   Bugliani, M ^a   Boggi, U ^a   Mosca, F ^a   Marchetti, P ^a,b   Del Prato, S ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

Free fatty acids; Glucotoxicity; Lipotoxicity; Messenger ribonucleic acid; Pancreatic islets; Peroxisome proliferator activated receptors; Polymerase chain reaction; Prostaglandin

Indexed keywords

CELL NUCLEUS RECEPTOR; FATTY ACID; INSULIN; MESSENGER RNA; OLEIC ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOSTASIS; DENSITY GRADIENT; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN TISSUE; INSULIN RELEASE; PANCREAS ISLET; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADIPOSE TISSUE; ADULT; AGED; BLOOD GLUCOSE; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PANCREAS; PROSTAGLANDIN D2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 1642414416     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00561.2002     Document Type: Article

References (54)

1. Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, and Tzukerman M. Insulin production by human embryonic stem cells. Diabetes 50: 1691-1697, 2001.
2. Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia 42: 1033-1049, 1999.
3. Ayvaz G, Balos Toruner F, Karakoc A, Yetkin I, Cakir N, and Arslan M. Acute and chronic effects of different concentrations of free fatty acids on the insulin secreting function of islets. Diabetes Metab 28: S7-S12, 2002.
4. Bjorklund A and Grill V. Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. Diabetes 48: 1409-1414, 1999.
5. Boden G, Chen X, Rosner J, and Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44: 1239-1242, 1995.
6. Bollheimer LC, Kemptner DM, Kagerbauer SM, Kestler TM, Wrede CE, and Buettner R. Intracellular depletion of insulin: a comparative study with palmitate, oleate and elaidate in INS-1 cells. Eur J Endocrinol 48: 481-486, 2003.
7. Bollheimer LC, Skelly RH, Chester MW, McGarry JD, and Rhodes CJ. Chronic exposure to free fatty acid reduces pancreatic β cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis traslation. J Clin Invest 101: 1094-1101, 1998.
8. Braissant O, Foufelle F, Scotto C, Dauca M, and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137: 354-366, 1996.
9. Buchanan TA, Xiang AH, Peters RH, Kjos SL, Berkowitz K, Marroquin A, Goico J, Ochoa C, and Azen SP. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 49: 782-788, 2000.
10. Carpentier A, Mittelman SD, Bergman RN, Giacca A, and Lewis GF. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 49: 399-408, 2000.
11. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, and Lewis GF. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol Endocrinol Metab 276: E1055-E1066, 1999.
12. Cavaghan MK, Ehrmann DA, KS, and Polonsky MM. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100: 530-537, 1997.
13. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, and Pipeleers̀ DG. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 50: 1771-1777, 2001.
14. Desvergne B and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688, 1999.
15. Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vanderwalle V, Desreumaux P, Auwerx J, Schoonjans K, and Lefebvre J. Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in normal human pancreatic islet cells. Diabetologia 43: 1165-1169, 2001.
16. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz MD, Moller DE, and Berger J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun 224: 431-437, 1996.
17. Elks ML. Chronic perifusion of rat islets with palmitate suppresses glucose-stimulated insulin release. Endocrinology 133: 208-214, 1993.
18. Finegood DT, MacArthur MD, Kojawang D, Thomas MJ, Topp BJ, Leonard T, and Buckingham RE. β-Cell mass dynamics in Zucker diabetic fatty rats. Diabetes 50: 1021-1029, 2001.
19. Frias JP, Basabe L, Macaraeg G, and Kruszynska YT. Lack of effect of a physiological elevation of plasma non-esterified fatty acid levels on insulin secretion. Diabetes Metab 26: 133-139, 2000.
20. Gravena C, Mathias PC, and Ashcroft SJ. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol 173: 73-80, 2002.
21. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zick K, Ferranini E, and DeFronzo RA. Glucose and free-fatty acid metabolism in non-insulin-dependent diabetes: evidence for multiple insulin resistance. J Clin Invest 84: 205-213, 1989.
22. Jensen CB, Storgaard H, Holst JJ, Dela F, Madsbad S, and Vaag AA. Insulin secretion and cellular glucose metabolism after prolonged low-grade Intralipid infusion in young men. J Clin Endocrinol Metab 88: 2775-2783, 2003.
23. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, and Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA 91: 10878-10882, 1994.
24. Lemberger T, Bralssant O, Juge-Aubry C, Keller H, Saladin R, Staels B, Auwerx J, Burger AG, Meier CA, and Wahli W. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann NY Acad Sci 804: 231-251, 1996.
25. Lupi R, Del Guerra S, Fierabracci V, Marselli L, Novelli M, Patanè G, Boggi U, Mosca F, Piro S, Del Prato S, and Marchetti P. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 51, Suppl 1: S134-S137, 2002.
26. Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, Carmellini M, Mosca F, Navalesi R, and Marchetti P. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 364: 205-209, 1999.
27. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, Patane G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario U, Del Prato S, and Marchetti P. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51: 1437-1442, 2002.
28. Maedler K, Oberholzer J, Bucher P, Spinas GA, and Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 52: 726-733, 2003.
29. Marchetti P, Dotta F, Ling Z, Lupi R, Del Guerra S, Santangelo C, Realacci M, Marselli L, Di Mario U, and Navalesi R. The function of pancreatic islets isolated from Type 1 diabetic patient. Diabetes Care 23: 701-703, 2000.
30. Mulder H, Hoist LS, Svensson H, Degerman E, Sundler F, Ahren B, Rorsman P, and Holm C. Hormone-sensitive lipase, the rate-limiting enzyme in triglyceride hydrolysis, is expressed and active in beta-cells. Diabetes 48: 228-232, 1999.
31. Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno G, Gambardella A, Giugliano D, D'Onofrio F, and Howard BV. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type 2 diabetes. Diabetologia 41: 1127-1132, 1998.
32. Prentki M and Corkey BE. Are the beta-cell signaling molecules malonyl-CoA and cytolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 45: 273-283, 1996.
33. Puigserver P and Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 24: 78-90, 2003.
34. Puigserver P, Wu Z, Park CW, Graves R, Wright M, and Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829-839, 1998.
35. + channels encoded by the Herg gene. FASEB J 14: 2601-26100, 2000.
36. Sako Y and Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127: 1580-1589, 1990.
37. Schoonjans K, Staels B, and Auwerx J. The peroxisome proliferator-activated receptor and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93-109, 1996.
38. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, and Unger RH. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 273: 32487-32490, 1998.
39. Shimabukuro M, Zhou YT, Lee Y, and Hunger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273: 3547-3550, 1998.
40. Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression. Postgrad Med 109: 55-59, 63-64, 2001.
41. Spiegelman BM, Puigserver P, and Wu Z. Regulation of adipogenesis and energy balance by PPARgamma and PGC-1. Int J Obes Relat Metab Disord 24, Suppl 4: S8-S10, 2000.
42. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Deleruive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393: 790-793, 1998.
43. Unger RH and Grundy S. Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 28: 119-121, 1985.
44. Unger RH and Orci L. Lipotoxic diseases of nonadipose tissues in obesity. Int J Obes Relat Metab Disord 24: S28-S32, 2000.
45. Unger RH and Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50: S118-S121, 2001.
46. Valmaseda A, Carmona MC, Barbera MJ, Vinas O, Mampel T, Iglesias R, Villaroya F, and Giralt M. Opposite regulation of PPAR-α and -γ gene expression by both their ligands and retinoic acid in brown adipocytes. Mol Cell Endocrinol 154: 101-109, 1999.
47. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, and Flier JS, Peroxisome proliferator-activated receptor gene expression in human tissue. J Clin Invest 99: 2416-2422, 1997.
48. Yang C, Chang TJ, Chang JC, Liu MW, Tai TY, Hsu WH, and Chuang LM. Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway. Diabetes 50: 2598-2602, 2001.
49. Yoon JC, Xu G, Deeney JT, Yang SN, Rhee J, Puigserver P, Levens AR, Yang R, Zhang CY, Lowell BB, Berggren PO, Newgard CB, Bonner-Weir S, Weir G, and Spiegelman BM. Suppression of beta cell energy metabolism and insulin release by PGC-1 alpha. Dev Cell 5: 73-83, 2003.
50. Zhou YP, Berggren PO, and Grill V. A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of beta-cell dysfunction in the obese diabetic db/db mouse. Diabetes 45: 580-586, 1996.
51. Zhou YP and Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93: 870-876, 1994.
52. Zhou YP and Grill V. Long-term exposure to fatty acids and ketones inhibits beta-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 80: 1584-1590, 1995.
53. Zhou YP, Ling ZC, and Grill VE. Inhibitory effects of fatty acids on glucose-regulated B-cell function: association with increased islet triglyceride stores and altered effect of fatty acid oxidation on glucose metabolism. Metabolism 45: 981-986, 1996.
54. Zhou YT, Shimabukuro M, Wang MY, Lee Y, Higa M, Milburn JL, Newgard CB, and Unger RH. Role of peroxisome proliferator-activated receptor ct in disease of pancreatic β cells. Proc Natl Acad Sci USA 95: 8898-8903, 1998.